Poster
Pipeline Compounds
ASCO 2026 | May 29 - June 2, 2026
Other/Multi
A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist antibody–drug conjugate,in patients with advanced/metastatic solid tumors
Shigehiro Koganemaru
Poster
Pipeline Compounds
ASCO 2026 | May 29 - June 2, 2026
Other/Multi
A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced/metastatic solid tumors (Parts 1 and 2)
Shiraj Sen
Oral
Dato-DXd
AACR 2026 | April 17-22, 2026
Other/Multi
Antitumor activity of datopotamab deruxtecan in a co-clinical trial with patient derived xenografts
Dhruv Chachad
Poster
Pipeline Compounds
AACR 2026 | April 17-22, 2026
Other/Multi
DS-2243a, an HLA-A*02/NY-ESO–directed bispecific T-cell engager, shows potent anti-tumor activity in preclinical models of solid tumors
Junya Ichikawa
Mini-Oral
Pipeline Compounds
JSMO 2026 | March 26-28, 2026
Other/Multi
DS-3939, a TA-MUC1 antibody–drug conjugate in advanced/metastatic solid tumors: Initial first-in-human results
Toshihiko Doi
Oral
Pipeline Compounds
ESMO 2025 | October 17-21, 2025
Other/Multi
DS-3939, a tumor-associated mucin 1 (TA-MUC1)–directed antibody–drug conjugate, in patients with advanced/metastatic solid tumors: Initial results from a first-in-human study
Manish R. Patel
Oral
HER3-DXd
JSMO 2026 | March 26-28, 2026
Other/Multi
HERTHENA-PanTumor01: Expansion of a global phase 2 trial of HER3-DXd in patients with advanced/metastatic solid tumors
Izuma Nakayama
Poster
T-DXd
AMCP Nexus 2025 | October 27-30, 2025
Other/Multi
Patient characteristics, treatment patterns, and real-world outcomes among patients in the US with human epidermal growth factor receptor 2-expressing solid tumors
Anuj Shah
Poster
T-DXd
ISPOR 2026 | May 17-20, 2026
Other/Multi
Patient preferences for treatment benefits in metastatic solid cancers: A systematic literature review
Alexandra Jager
Oral
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Other/Multi
Trastuzumab deruxtecan in patients with HER2-low recurrent/metastatic salivary gland carcinoma: Results from the phase II MYTHOS trial
Ichiro Kinoshita